AU7537101A - Powder compositions - Google Patents

Powder compositions

Info

Publication number
AU7537101A
AU7537101A AU7537101A AU7537101A AU7537101A AU 7537101 A AU7537101 A AU 7537101A AU 7537101 A AU7537101 A AU 7537101A AU 7537101 A AU7537101 A AU 7537101A AU 7537101 A AU7537101 A AU 7537101A
Authority
AU
Australia
Prior art keywords
powder compositions
compositions
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU7537101A
Other versions
AU2001275371B2 (en
AU2001275371B9 (en
Inventor
Yuh-Fun Maa
Lu Zhao
Steven Joseph Prestrelski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Powderject Vaccines Inc
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Publication of AU7537101A publication Critical patent/AU7537101A/en
Publication of AU2001275371B2 publication Critical patent/AU2001275371B2/en
Application granted granted Critical
Publication of AU2001275371B9 publication Critical patent/AU2001275371B9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2001275371A 2000-06-08 2001-06-08 Powder compositions Ceased AU2001275371B9 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21058100P 2000-06-08 2000-06-08
US59077700A 2000-06-08 2000-06-08
US09/590,777 2000-06-08
US60/210,581 2000-06-08
PCT/US2001/018494 WO2001093829A2 (en) 2000-06-08 2001-06-08 Powder compositions

Publications (3)

Publication Number Publication Date
AU7537101A true AU7537101A (en) 2001-12-17
AU2001275371B2 AU2001275371B2 (en) 2006-12-21
AU2001275371B9 AU2001275371B9 (en) 2007-06-07

Family

ID=26905296

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275371A Ceased AU2001275371B9 (en) 2000-06-08 2001-06-08 Powder compositions

Country Status (11)

Country Link
EP (1) EP1289494A2 (en)
JP (1) JP2003535119A (en)
KR (1) KR20030020294A (en)
CN (1) CN1438874A (en)
AU (1) AU2001275371B9 (en)
BR (1) BR0111494A (en)
CA (1) CA2412197A1 (en)
IL (1) IL153241A0 (en)
MX (1) MXPA02012039A (en)
NZ (2) NZ523103A (en)
WO (1) WO2001093829A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532277A (en) * 2001-06-08 2004-10-21 パウダージェクト ワクチンズ，インコーポレーテッド Spray freeze-dried composition
EP1458362A4 (en) * 2001-11-19 2006-01-18 Becton Dickinson Co Pharmaceutical compositions in particulate form
AU2003234090A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
DE10339197A1 (en) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried amorphous powder with low residual moisture and good storage stability
MX2007003726A (en) * 2004-09-28 2007-06-15 Johnson & Johnson Stabilization of alum-adjuvanted immunologically active agents.
AU2006261669B2 (en) * 2005-06-27 2011-07-07 Applied Thin Films, Inc. Aluminum phosphate based microspheres
CA2624503A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
WO2007053781A2 (en) * 2005-11-01 2007-05-10 Novartis Ag Compositions with antigens adsorbed to calcium phosphate
JP2010502747A (en) * 2006-09-08 2010-01-28 ベクトン・ディキンソン・アンド・カンパニー A stable powder formulation of alum-adsorbed vaccine
EP3590503A1 (en) 2006-10-12 2020-01-08 The University of Queensland Compositions and methods for modulating immune responses
CA2681567C (en) 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
CA2694083A1 (en) * 2007-07-26 2009-01-29 Sanofi Pasteur Limited Antigen-adjuvant compositions and methods
CA2716399C (en) 2008-03-05 2020-07-21 Pierre Chouvenc Process for stabilizing an adjuvant containing vaccine composition
AU2009299615B2 (en) 2008-10-02 2015-07-16 Pharmathene Inc. Anthrax vaccine formulation and uses thereof
GB2499479A (en) 2010-03-31 2013-08-21 Stabilitech Ltd Stabilisation of viral particles
ES2708989T3 (en) * 2010-03-31 2019-04-12 Stabilitech Biopharma Ltd Method of preservation of alum adjuvants and alum-enhanced vaccines
DK2552478T3 (en) 2010-03-31 2017-03-27 Stabilitech Ltd EXCIPIENTS FOR STABILIZING VIRUS PARTICLES
BR112013010926A2 (en) 2010-11-01 2016-08-23 Univ Technology Sidney immunomodulatory agents and their uses
AU2011336413B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
KR102023207B1 (en) 2010-12-02 2019-11-25 온콜리틱스 바이오테크 인코포레이티드 Lyophilized viral formulations
CN102133396B (en) * 2011-03-16 2013-10-16 中国人民解放军第三〇二医院 Vaccine injection and preparation method thereof
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
EP2822540B1 (en) * 2012-03-05 2020-04-08 De Staat der Nederlanden, Vert. Door de Minister van VWS Methods and compositions for stabilizing dried biological materials
KR101441539B1 (en) * 2013-04-01 2014-09-18 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 Adhesive compositions having improved hygroscopicity and preparation methods thereof
CN103641886B (en) * 2013-11-26 2015-07-29 精晶药业股份有限公司 A kind of process for purification of glutamine dipeptide
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (en) * 1981-05-13 1982-11-19 Pasteur Institut IMPROVEMENTS IN LIVE STABILIZING AGENTS FOR THE PREPARATION OF VACCINES, AND STABILIZED VACCINES CONTAINING SAID STABILIZING AGENTS
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
JPS6013718A (en) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst B-type hepatitis vaccine
EP0676088A1 (en) * 1992-12-28 1995-10-11 YU, Shih-Chiang Non-volatile semiconductor memory cell
EP0678035B9 (en) * 1993-01-08 2006-12-13 Csl Limited Vaccine preparations
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
RU2096042C1 (en) * 1996-11-06 1997-11-20 Виктор Иванович Ситьков Method of preparing multipartial vaccine for leptospirosis control in animals
CN1285753A (en) * 1997-12-02 2001-02-28 鲍德杰克特疫苗公司 Transdermal delivery of particulate vaccine compositions

Also Published As

Publication number Publication date
CA2412197A1 (en) 2001-12-13
JP2003535119A (en) 2003-11-25
NZ552576A (en) 2008-06-30
AU2001275371B2 (en) 2006-12-21
IL153241A0 (en) 2003-07-06
MXPA02012039A (en) 2003-06-06
NZ523103A (en) 2005-08-26
EP1289494A2 (en) 2003-03-12
CN1438874A (en) 2003-08-27
WO2001093829A2 (en) 2001-12-13
KR20030020294A (en) 2003-03-08
WO2001093829A3 (en) 2002-06-13
BR0111494A (en) 2004-01-13
AU2001275371B9 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
IL153241A0 (en) Powder compositions
GB0010227D0 (en) Pouched compositions
GB0010249D0 (en) Pouched compositions
EP1341554A4 (en) Colostrum-based composition
GB0011084D0 (en) Cosmetic compositions
GB0016937D0 (en) Antiperspirant compositions
EP1320385A4 (en) Combination compositions
GB0010220D0 (en) Pouched compositions
EP1270611A4 (en) Composition
GB0019651D0 (en) Compositions
GB2376022B (en) Powder coating compositions
GB0025439D0 (en) Cosmetic compositions
GB0016067D0 (en) Oral compositions
EP1269969A4 (en) Cosmetic compositions
AU2001287852A8 (en) Composition
GB2376021B (en) Powder coating compositions
GB0004518D0 (en) Compositions
GB2372518B (en) Powder composition
GB0022297D0 (en) Oral compositions
HK1077767A1 (en) Deodorant compositions
EP1267814A4 (en) Composition
GB0031267D0 (en) Novel compositions
GB0004522D0 (en) Compositions
GB0001854D0 (en) Compositions
GB0017288D0 (en) Compositions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
SREP Specification republished
SREP Specification republished
MK14 Patent ceased section 143(a) (annual fees not paid) or expired